- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
You are here
SSPN formulations of novel emtricitabine
Phase
Pre-clinical
Objective
Preclinical assessment of LAI semi-solid prodrug nanoparticle (SSPN) formulations of novel emtricitabine (FTC) prodrugs to prevent HIV infection.
Prevention Option(s)
PrEP
Arms and Assigned Interventions
Description
Animals received 140 mg/kg FTC equivalent (SSPN 9 or 10) via 2 intramuscular injections vs an untreated control (n= 7-6 per group).
Mode of Delivery
Biojector
Products
emtricitabine
Related Publications
Product Developers
University of Liverpool